Terms used in this guideline
This section defines terms that have been used in a particular way for this guideline.
Active psoriatic arthritis
Peripheral arthritis with 3 or more tender joints and 3 or more swollen joints.
Biological DMARD
A biological disease-modifying anti-rheumatic drug (DMARD) is any DMARD made by or derived from a biological (natural) source, for example, an animal cell or microorganism. This includes the anti-lymphocyte monoclonal antibodies, interleukin inhibitors and TNF-alpha inhibitors. Examples include bimekizumab and secukinumab (interleukin inhibitors), and adalimumab, golimumab and infliximab (TNF-alpha inhibitors).
Janus kinase (JAK) inhibitor
A targeted synthetic DMARD that inhibits the inflammatory activity of the Janus kinase enzymes. They are given orally. Examples include upadacitinib and tofacitinib.
Tumour necrosis factor (TNF)-alpha inhibitor
A biological DMARD that inhibits an inflammatory protein, tumour necrosis factor-alpha. They are given by injection or infusion. Examples include adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab.